Feed ARVN
AR

Arvinas, Inc.

ARVN · NASDAQ

$7.74 +2.45% (+$0.19)
1M -18.48%
Market Cap $483.9M
P/E Ratio 52.03x
Div. Yield -
ROE 1.91%
Analiza

AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.

Piotroski F-Score Moderate
6/9
Valuation
29 /100
Expensive
P/S 1.53x
P/E 52.03x
P/B 0.86x
Growth
78 /100
Growing
Book val. growth 8.43%
Rev. growth 25.96%
FCF growth N/A
Profitability
25 /100
Weak
Op. margin 4.45%
Gross margin 96.43%
FCF margin 65.93%
Quality
10 /100
Poor
ROA 1.38%
ROIC 2.18%
Asset turnover 0.47x
Debt
100 /100
Low
Net debt/EBITDA -29.76x
Debt/Equity 0.01x
Current ratio 7.91x
Stability
16 /100
Unstable
EPS volatility 46.61%
Beta 1.76x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o ARVN
Online

O podjetju

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Randy Teel

Employees

246

Headquarters

New Haven

Prihajajoči dogodki

04 NOV.

Earnings

Upcoming earnings report

35d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.